Kornimate/medical-research-clean huggingface dataset:
percutaneous neuromodulation on the anterior pain knee

Conditions: Neuromodulation; Anterior Pain Knee; Femoral Nerve

Summary: anterior knee pain (akp) is one of the most frequent pathologies of the lower limb, in young and adult subjects. in the field of physiotherapy, ultrasound-guided percutaneous neuromodulation (pnm) is defined as the application through a needle with ultrasound guidance of an electrical current at low or medium frequency, seeking a sensitive and / or motor response of a peripheral nerve in some point of its trajectory, or of a muscle in a motor point, with a therapeutic objective. the objective of this study is to analyze that the effect of pnm on the femoral nerve produces statistically significant changes in pain, joint range and knee functionality in patients with chronic akp. thirty subjects will be recruited, which will be divided into 2 groups: group 1 to which pnm will be applied to the femoral nerve of the pain knee; and group 2 to which pnm will be applied to the femoral nerve of the non-pain knee. the pnm intervention with nmp will consist in the single application of an asymmetric rectangular biphasic current (250 microseconds, 10 hz)


Eligibility criteria:
inclusion criteria: * chronic anterior knee pain \>3 months * older than 18 years-old exclusion criteria: * surgical intervention in the intervention area * prosthesis or osteosynthesis in the intervention area * cardiac or tumoral diseases * coagulopathies * be under the effects of certain medications * contraindication characteristic of the puncture
ephedrine doses to prevent maternal hypotension after spinal anesthesia in cesarean section

Conditions: Hypotension After Spinal Anesthesia; Hypotension During Cesarean Delivery

Summary: this randomized controlled trial aims to compare the effectiveness of different doses of ephedrine infusion in preventing maternal hypotension following spinal anesthesia in parturients undergoing cesarean sections. the study includes 120 participants, aged 18-40 years, with american society of anesthesiologists (asa) physical status ii, who are scheduled for elective cesarean delivery. the primary objective is to determine whether low-dose ephedrine infusions at 1.25 mg/min or 1.5 mg/min effectively reduce the incidence of maternal hypotension, with secondary outcomes assessing the need for rescue ephedrine, incidence of side effects (nausea, vomiting, tachycardia), and neonatal apgar scores. researchers will compare three groups-saline, 1.25 mg/min ephedrine, and 1.5 mg/min ephedrine-to evaluate their impact on maternal hemodynamic stability.


Eligibility criteria:
inclusion criteria: * patients undergoing cesarean section * self-identified as female * american society of anesthesiologists (asa) physical status ii * aged between 18 to 40 years * full-term singleton pregnancies planned for cesarean delivery under spinal anesthesia exclusion criteria: * body mass index (bmi) ≥ 40 kg/m² * height less than 145 cm * presence of severe neurological or psychiatric conditions * history of pre-eclampsia * severe renal or metabolic disorders * contraindications to spinal anesthesia * antenatal evidence of fetal anomalies * cases with severely compromised fetuses requiring immediate general anesthesia * baseline systolic blood pressure (sbp) less than 90 mm hg * pregnancy-induced hypertension * refusal to provide written consent
deep brain stimulation for patients with dementia with lewy bodies

Conditions: Dementia With Lewy Bodies

Summary: this trial aims to collect pilot data to explore whether bilateral deep brain stimulation (dbs) of the nucleus basalis of meynert (nbm) has beneficial effects on memory and thinking impairments among individuals with dementia with lewy bodies (dlb).

we will perform a pilot study to evaluate the effectiveness of human nbm dbs at improving cognitive deficits in dlb patients. six patients with dlb with moderate cognitive impairments (including but not restricted to deficits in attention and working memory) will have bilateral dbs electrodes implanted to ensure that superficial contacts lie in the motor globus pallidum interna (gpi) target, while the deepest electrical contacts lie in the nbm. we will place electrodes using our conventional image-guided, stereotactic frame-based procedure. once the surgical wounds have healed, patients will be randomised into 2 groups in a crossover trial design to have 6 week periods of nbm stimulation switched on or switched off separated by a 2 week washout period, following which the patient will cross over to have the opposite condition for a further 6 weeks. outcome measures collected at the 6 weeks and 14 weeks timepoints will be compared according to whether each patient was on or off stimulation at that timepoint. at the end of the crossover period, all patients will be invited for continued follow up with stimulation switched on and will have neuropsychological evaluations at 6 monthly intervals. patients will be given the option of receiving additional conventional stimulation to the motor gpi, through the higher contacts of each electrode, at the end of the crossover period if required for any coexisting parkinsonian motor complications of dlb.

Eligibility criteria:
inclusion criteria: * dlb consortium criteria for diagnosis * score between 2 \& 12 on clinician assessment of fluctuations scale * mmse score between 21 and 27 * appropriate surgical candidates in terms of general health * aged between 50 \& 80 * able to give informed consent * living at home with carer * able to comply with protocol * on stable dosage of cholinesterase inhibitor exclusion criteria: * diagnosis of other cause for dementia * abnormality on brain imaging considered likely to compromise compliance with trial protocol. * prior intracerebral surgical intervention
comparison of raloxifene and lasofoxifene - a randomized, blinded study of these drugs and placebo on bone loss

Conditions: Osteoporosis

Summary: to compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (bmd) of the lumbar spine.


Eligibility criteria:
inclusion criteria: * postmenopausal women with low bone density (osteopenia) and screening labs, pelvic ultrasound, mammogram without significant findings exclusion criteria: * presence of metabolic bone disease, fractures, blood clots, or recent cancer. * any use of selective estrogen receptor modulators, investigational drugs, or recent use of osteoporosis treatments, certain hormones, or medication for blood clots or seizures.
dlbcl interim response evaluation for customised therapy

Conditions: High-grade B-cell Lymphoma

Summary: the aim of the direct study is to establish a robust pipeline to identify those patients with high-grade b cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy.

this will be done by integrating data and samples collected from patients undergoing standard of care treatment for high-grade b cell lymphoma data will be integrated from 1. clinical risk factors from the international prognostic index (ipi) 2. up-front genomic subtype based on molecular profiling of diagnostic biopsy 3. serial ctdna monitoring during treatment. 4. radiological response imaging

Eligibility criteria:
* have given written informed consent to participate. * age ≥ 18 years at the time of consent. * histologically confirmed diagnosis of previously untreated high-grade b cell lymphoma. * planned to receive immunochemotherapy as first-line therapy, e.g. r-chop therapy. * planned or completed standard of care imaging (ct or pet-ct) * able to give blood. exclusion criteria: * unable to receive immunochemotherapy as first-line therapy due to co-morbidity or personal choice. * patients who have already started high dose steroids as a treatment for their lymphoma. * known diagnosis of infectious blood-borne virus e.g. hep b, hep c or hiv.
folfox4 combined with endostar in patients with advanced colorectal cancer

Conditions: Colorectal Neoplasms

Summary: folfox4 plus avastin has been suggested as firstline regimen for advanced colorectal cancer by nccn, a new angiogenesis inhibitor, known as endostar(recombinant human endostatin), prolonged the overall survival, time to progression and improved response rate in metastatic lung cancer in a large phase iii clinical trial in china, so we design this trial to evaluate the safty and efficacy of folfox4 plus endostar in patients with advanced colorectal cancer

endostar is free supported by shangdong simcere medgene biotech co.,ltd. endostar combination with chemotherapy has been the first line treatment regimen to advanced nsclc. clinical data proved that endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent human genome. china nccn colon or rectal cancer clinical practice guideline recommends chemotherapy plus angiogenesis inhibitor as the first line treatment scheme. so we design folfox4 plus endostar to treat advanced colorectal cancer to research the rr and safety. we believe this treatment regimen may be a new approach to the advanced colorectal cancer patients.

Eligibility criteria:
inclusion criteria: * patients with histologically or cytologically confirmed metastatic crc * measurable disease according to response criteria in solid tumours (recist) * performance status 0 - 2 according to ecog (eastern cooperative oncology group) performance status * age 18\~75 * life expectancy \> 3 months * signed informed consent (ic) * adequate haematological and biological functions exclusion criteria: * pregnant or lactating women * known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs * neuropathy, brain, or leptomeningeal involvement * treatment with any biologic, cytotoxic, radiation , or hormonal therapy within four weeks. * clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or high risk/uncontrolled arrhythmia * uncontrolled significant comorbid conditions and previous radiotherapy

Keywords: colorectal cancer chemotherapy recombinant human endostatin
dysphotopsia following laser peripheral iridotomy

Conditions: Narrow Angle Patients at Risk for Angle Closure Glaucoma

Summary: to establish the correlation of the location of the nd:yag laser peripheral iridotomy to the post operative visual symptoms experienced by some patients. the investigators hypothesize that fully uncovered laser peripheral iridotomy will produce less significant dysphotopsia, due to avoidance of the prismatic effect produced by the tear film than those covered.

nd:yag lpi is a frequently performed procedure for patients who have narrow angles at risk of acute angle closure glaucoma, pupillary-block conditions, chronic angle closure, and pigment dispersion syndrome. most complications associated with the procedure are benign and include intraocular pressure (iop) spike, transient uveitis, hyphema, corneal or lens damage and closure of the iridotomy. visual disturbances have been also reported but only a few papers address this specific issue. the rate of these symptoms vary between 2.7% and 4%. it is believed that these symptoms are associated with the fact that light enters through the lpi and thus creating abnormal visual symptoms. hence it has been suggested to carefully place the lpi so that the eyelid fully covers the lpi, therefore preventing light getting through. however, reports of patients with fully covered lpis and visual disturbances have led to hypothesize the theory that even when fully covered by the eyelid, light can access through the lpi by a base-up prism created by the tear meniscus at the lid margin. therefore, placement of the lpi, fully covered, partially covered or totally uncovered can potentially lead to equally significant symptoms. this study will attempt to address the issue of placement of the lpi in relationship with visual symptoms.

Eligibility criteria:
inclusion criteria: * able and willing to make the required study visit * able and willing to give consent and follow study instructions * an indication to undergo laser peripheral iridotomy (narrow angles, occludeable angle at risk of acute angle closure, pupil block condition, chronic angle closure, pigment dispersion syndrome) exclusion criteria: * previous intraocular surgery * best corrected visual acuity worse than 20/40 * asymmetrical ptosis of more than 2mm * any active intraocular inflammation * acute attack of angle closure glaucoma

Keywords: laser peripheral iridotomy visual dysphotopsia visual disturbances angle closure glaucoma
single dose versus two weeks course of fluconazole in the treatment of oropharyngeal candidiasis in hiv infected individuals in tanzania

Conditions: Oropharyngeal Candidiasis

Summary: a prospective randomized double blinded placebo controlled comparative trial will be performed at hiv clinic of the muhimbili national hospital/muchs where 220 hiv positive patients presenting with oropharyngeal candidiasis (opc) on antiretroviral (arvs) treatment or not will be included. the aim of this study is to compare the efficacy and safety of single dose fluconazole (750mg) and two weeks course of fluconazole (150mg once daily)in the treatment of opc in hiv positive patients. it is hypothesised that the two regimens are equally effective in the treatment of opc.

a structured standard questionnaire will be used to systematically collect essential data including demography, treatment history and concomitant infections and treatment. general and oral examination, collection of oral isolates, mycological, hematological and biochemical investigations will be done at baseline and at end of treatment day 13-14. all patients will be followed up to 30 days after end of treatment for relapse

Eligibility criteria:
inclusion criteria: * hiv infection (as determined by positive elisa and confirmed by western blot) * 18 years of age and above * clinical picture of opc, characterized by creamy, white, curd like patches, removable by scraping or by typical erythematous lesions (smooth red patches) on the oral mucosa, hard or soft palate and/or dorsal surface of the tongue; and microbiologically by visualization of yeast cells in potassium hydroxide (10% koh) preparations prepared from swab of visible lesions and confirmed positive candida species culture exclusion criteria: * patients who are currently receiving antifungal therapy or who had received such treatment within three days prior to enrollment in this study * history of allergy to azole derivatives * abnormal liver function tests defined as alanine aminotransferase (alt), aspartate aminotransferases (ast), or total bilirubin greater than three times the upper limit of normal; or clinical evidence of significant hepatic or renal disease within two months prior to enrollment * inability to tolerate oral drug administration; pregnancy or breast feeding; life expectancy of less than four weeks * participation in another drug study at the time of enrollment, treatment with drug which interact with fluconazole, such as vitamin k antagonists, warfarin, sulfonylurea anti-diabetic agents, rifampicin, phenytoin, isoniazid, carbamazepine and cisapride * documented systemic fungal infections, symptoms suggestive of esophageal candidiasis such as retrosternal chest pain, dysphagia or odynophagia unless this condition has been ruled out by endoscopic examination. * patients with history of alcohol abuse, drug addiction and psychiatric disorder, inability to cooperate and poor motivation will be excluded from the study.

Keywords: oropharyngeal candidiasis
pexelizumab in conjunction with angioplasty in acute myocardial infarction (apex-ami)

Conditions: Acute Myocardial Infarction

Summary: in the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (pci), the body's own inflammatory system involving the complement cascade may be harmful. this study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to reduce mortality at 30 days.


Eligibility criteria:
inclusion criteria: * cardiac symptoms for at least 20 minutes within past 6 hours; * will undergo primary pci; * has ecg evidence of acute high risk st elevation myocardial infarction; * willing and able to be followed for at least 12 months. exclusion criteria: * isolated low risk inferior wall myocardial infarction; * received fibrinolytic therapy; * history of complement deficiency; * suspected neisserial infection; * participating in other investigational study; * pregnancy; * previous enrollment.
a research study in saudi arabia to understand how the dose check app used with tresiba treatment helps to control blood sugar level

Conditions: Diabetes Mellitus, Type 2

Summary: this study looks at how a mobile based app called 'dose check' used along with tresiba helps to control blood sugar level in participants with type 2 diabetes mellitus. participants will get tresiba as prescribed by the study doctor or participants will continue already prescribed treatment with tresiba. participants will also be prescribed to use dose check app by the study doctor and will be asked to install the dose check app in their mobile phone, which will support participants with the correct dose of tresiba. this study will last for about 6 to 7 months.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * male or female, age above or equal to 21 years at the time of signing informed consent. * diagnosed with type 2 diabetes mellitus (t2dm) above or equal to 12 weeks prior to signing consent. * the decision to initiate treatment with commercially available dose check app as a part of treatment along with tresiba as per the local label, has been made by the participant and the treating physician before and independently from the decision to include the participant in this study. * available hba1c value less than or equal to 12 weeks prior to the 'informed consent and initiation of dose check app visit' (v1) or hba1c measurement taken in relation with the 'informed consent and initiation of dose check app visit (v1)' (v1) or planned soon after v1 (less than or equal to 7 days), if in line with local clinical practice. * willingness to continue using the dose check app on a compatible smartphone according to the intended use for the entire duration of the study. exclusion criteria: * previous participation in this study. participation is defined as having signed informed consent in this study. * women known to be pregnant or breastfeeding, or women planning to become pregnant during the conduct of the study. * treatment with any investigational drug or software as medical device (samd) within 30 days prior to enrolment into the study. * diagnosed with type 1 diabetes mellitus. * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * hypersensitivity to the active substance or any of the excipients as specified in the tresiba local label. * on treatment with tresiba for above 3 months or at dose above 20 units at informed consent and initiation of dose check app visit (v1).
pelvic varicose veins treated with vascular plugs type amplatzer: repivac

Conditions: Pelvic Congestion Syndrome; Pelvic Varicose Veins; Follow-up Study; Embolization, Therapeutic; Observational Study

Summary: spanish multicentric record to study the efficacy and safety of the treatment with plugs in pelvic congestion syndrome.

this is an prospective observational study of patients that have been treated with plugs (type amplazer) at least one of the pelvic varicose veins. patients are recruited when the plug is implanted, and the investigators perfom a patients follow-up during 1, 3, 6, 12, 24 months

Eligibility criteria:
inclusion criteria: * female \< 18 years * present symptomatology * at least one image diagnosis exclusion criteria: * female \> 18 * non present symptomatology * non diagnosis

Keywords: pelvic congestion syndrome amplatzer vascular plug vascular plug metallic embolization device chronic pelvic pain embolization procedure
optimised fluoride prevention by double rinse with fluoride and calcium

Conditions: Dental Caries

Summary: aim: to determine the optimal ca2+ concentration with 905 ppm f as naf. study design: experimental study in 10 volunteers. single blind mouth rinse with calcium lactate solution (150; 75; 0 mm ca-lactate) is immediately followed by a standard fluoride rinse. procedure: rinses are performed in the evening. the rinse combinations are given in a random order, and the subjects are unaware of the sequence. at least 3 days separates the use of each rinse. dosage: 20 ml and 1 minute rinse with each solution. saliva samples: twelve hours after rinsing, unstimulated saliva samples are collected by expectoration. analysis: the fluoride concentration in saliva samples are analysed statistics and data handling: fluoride in saliva 12 hours after rinsing are examined by one-way anova, repeated measures design.


Eligibility criteria:
inclusion criteria: * 18 years or older * 10 natural teeth or more * willing to refrain from use of fluoride containing products * signed informed consent exclusion criteria: * less than 10 natural teeth * reduced cognitive skills * does not speak and/or understand swedish * ongoing oral or systemic infections * pregnancy * breast feeding

Keywords: dental caries/prevention and control oral health cariostatic agents
clinical follow-up after acl reconstruction

Conditions: Deficiency of Anterior Cruciate Ligament; Injury of Anterior Cruciate Ligament

Summary: no former studies have done long-term evaluation on patients reconstructed with hamstrings graft, the use of howells tibial guide and transtibial drilling of the femoral graft tunnel. the investigators aim to evaluate clinical, radiographic and subjective outcome at a minimum of 10 years after surgery. according to former published studies on alike methods, the use of transtibial drilling of the femoral graft tunnel causes an increased rotational instability of the knee. the investigators aim to map the clinical stability of this group as well as evaluating the general outcome at the long-time horizon.

patients will be invited to a clinical follow-up with x-ray of the knee, scoring of lysholm and ikdc subjective scores, clinical examination including instrumented testing with a kt-1000. after informed consent data will be collected from patient records and stored in a secured internal database. analysis will be done with the spss package.

Eligibility criteria:
inclusion criteria: - patients reconstructed with the given technique exclusion criteria: * patients reconstructed with other techniques * concomitant ligamental surgery * bilateral acl injury * revision surgery